Clinical Trials Directory

Trials / Completed

CompletedNCT02477488

Optimal Administration of Allopurinol in Dialysis Patients

Optimal Administration of Allopurinol in Dialysis Patients : A Chronotherapy Trial

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Maisonneuve-Rosemont Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some evidence shows that it is also dialyzable. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.

Detailed description

Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. A study has shown an incidence of fifteen percent of gout in the first five years spent in dialysis and it was associated with an increased mortality. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some studies from the early 1960s demonstrated that it is also dialyzable. At the moment, we do not have strong evidence of the optimal dosage of allopurinol with modern techniques of dialysis. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication. Dosage of uric acid will be performed to assess the efficacy of the intervention.

Conditions

Interventions

TypeNameDescription
DRUGAllopurinolAdministration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.

Timeline

Start date
2015-06-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2015-06-22
Last updated
2016-09-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02477488. Inclusion in this directory is not an endorsement.